Researchers developed a prediction tool that identifies which psoriasis patients are at highest risk for weak bones (osteoporosis) with 77% accuracy. According to Gram Research analysis of 639 psoriasis patients, six key factors—including age, vitamin D levels, steroid use, and disease duration—predict bone loss risk. This tool could help doctors decide who needs bone density screening and early preventive treatment to avoid fractures.
People with psoriasis—a skin condition that causes inflammation—have a higher chance of developing weak bones (osteoporosis). Researchers studied 639 psoriasis patients to create a simple prediction tool that doctors can use to identify who’s at highest risk. The tool looks at six key factors including age, how long someone has had psoriasis, vitamin D levels, and certain medications. According to Gram Research analysis, this new tool could help doctors catch bone problems early and prevent serious fractures before they happen.
Key Statistics
A 2026 cohort study of 639 psoriasis patients found that 11.7% had osteoporosis, with a newly developed prediction tool achieving 77.1% accuracy in identifying high-risk individuals in a validation group.
According to research reviewed by Gram, vitamin D deficiency increased osteoporosis risk about 5 times in psoriasis patients, while systemic corticosteroid use increased risk 3.5 times in the 639-patient cohort study.
A 2026 study of 639 psoriasis patients found that advanced age was the strongest predictor of bone loss, increasing osteoporosis risk approximately 4 times compared to younger patients.
In a 2026 validation study of 192 psoriasis patients, the new prediction nomogram demonstrated good discrimination with an AUC of 0.771, confirming its clinical utility for identifying osteoporosis risk.
The Quick Take
- What they studied: Can doctors predict which psoriasis patients will develop weak bones using a simple scoring tool?
- Who participated: 639 people with psoriasis treated between January 2023 and October 2025. The group was split into a training group (447 people) to build the tool and a testing group (192 people) to check if it worked.
- Key finding: The prediction tool successfully identified bone loss risk with 82.4% accuracy in the training group and 77.1% accuracy in the testing group. About 1 in 8 psoriasis patients (11.7%) had osteoporosis.
- What it means for you: If you have psoriasis, your doctor may soon be able to use this tool to determine if you need bone density screening. Early detection could lead to preventive treatments that keep your bones strong. However, this tool needs to be tested in more diverse patient groups before widespread use.
The Research Details
Researchers looked back at medical records from 639 psoriasis patients seen between January 2023 and October 2025. They split the patients into two groups: a larger training group (447 patients) used to develop the prediction tool, and a smaller validation group (192 patients) used to test whether the tool actually worked on new patients.
They measured bone density using a standard imaging test called DXA (dual-energy X-ray absorptiometry), which is like a special X-ray that shows how dense your bones are. Doctors consider bones weak when the DXA score drops below -2.5.
The researchers then used statistical analysis to find which factors best predicted bone loss. They tested six key factors: age, how long someone had psoriasis, whether they had psoriatic arthritis (joint inflammation from psoriasis), vitamin D levels, use of steroid medications, and sex. Finally, they created a simple scoring system (called a nomogram) that doctors can use to estimate each patient’s risk.
This approach is important because it combines psoriasis-specific risk factors with general bone health factors. Previous tools didn’t account for how psoriasis itself and its treatments affect bone health. By testing the tool on a separate group of patients, the researchers proved it works reliably in real-world situations, not just in the original study group.
The study has several strengths: it used a large sample size (639 patients), split the data into training and testing groups to prevent overfitting, and used multiple statistical methods to verify the tool’s accuracy. However, the study only included patients from one healthcare system during a specific time period, so results may not apply equally to all populations. The study was also retrospective (looking backward at records) rather than following patients forward in time.
What the Results Show
The prediction tool identified six independent risk factors for bone loss in psoriasis patients. Advanced age was the strongest predictor—older patients were about 4 times more likely to have weak bones. Vitamin D deficiency was the second strongest factor, increasing risk about 5 times. Using systemic corticosteroid medications (steroids taken by mouth or injection) increased risk about 3.5 times.
Having psoriatic arthritis (when psoriasis affects the joints) more than doubled the risk of bone loss. Each additional year of having psoriasis increased risk by about 7%. Interestingly, being male actually reduced the risk compared to being female—men were about 60% less likely to have osteoporosis in this study.
When tested on new patients, the prediction tool worked very well. It correctly identified bone loss risk 77% of the time in the validation group. The tool’s predictions matched actual bone density measurements closely, suggesting it could reliably guide clinical decisions about who needs bone density screening.
The overall prevalence of osteoporosis in the psoriasis population was 11.7% (75 out of 639 patients), which is notably higher than in the general population. The tool showed excellent calibration, meaning its predictions accurately reflected real-world outcomes. Decision curve analysis confirmed the tool would be useful in clinical practice for guiding screening decisions.
This is one of the first tools specifically designed to predict bone loss in psoriasis patients. Previous research showed psoriasis increases osteoporosis risk, but doctors lacked practical tools to identify high-risk individuals. This nomogram fills that gap by combining psoriasis-specific factors (disease duration, psoriatic arthritis, steroid use) with traditional bone health factors (age, vitamin D, sex).
The study only included patients from one healthcare system, so results may not apply equally to different populations or geographic regions. The study was retrospective, meaning researchers looked back at existing records rather than following patients forward. The validation group was relatively small (192 patients). The tool needs testing in diverse populations and different healthcare settings before doctors widely adopt it. Additionally, the study didn’t examine all possible risk factors, such as lifestyle factors (exercise, diet, smoking) or other medications that might affect bone health.
The Bottom Line
If you have psoriasis, discuss with your doctor whether you should be screened for bone loss, especially if you have risk factors like advanced age, vitamin D deficiency, psoriatic arthritis, or long-term steroid use. This tool may help your doctor decide if DXA screening is appropriate. If bone loss is detected, preventive treatments like calcium and vitamin D supplementation, exercise, and medication may help maintain bone strength. (Confidence: Moderate—the tool shows promise but needs broader testing.)
This research matters most for people with psoriasis, especially those over 50, those who’ve had psoriasis for many years, those taking steroid medications, or those with psoriatic arthritis. It’s also relevant for dermatologists and rheumatologists who treat psoriasis patients. People without psoriasis don’t need to apply these findings, though the general risk factors (age, vitamin D, sex) apply to bone health broadly.
If you’re identified as high-risk and start preventive treatments, bone density improvements typically take 1-2 years to become measurable. Fracture prevention benefits may take longer to demonstrate. Early intervention is key—preventing bone loss is easier than reversing it.
Frequently Asked Questions
Do people with psoriasis have higher risk of weak bones?
Yes. Research shows psoriasis patients have significantly elevated osteoporosis risk. In a 2026 study of 639 psoriasis patients, 11.7% had osteoporosis. Chronic inflammation from psoriasis, combined with steroid medications and vitamin D deficiency, increases bone loss risk substantially.
What factors predict bone loss in psoriasis patients?
Six key factors predict osteoporosis risk in psoriasis: advanced age (4x higher risk), vitamin D deficiency (5x higher risk), systemic steroid use (3.5x higher risk), psoriatic arthritis (2x higher risk), longer disease duration, and female sex. A new prediction tool combines these factors to estimate individual risk.
Can doctors use a tool to predict who will get osteoporosis from psoriasis?
Yes. Researchers developed a prediction nomogram that identifies high-risk psoriasis patients with 77% accuracy. This tool helps doctors decide who needs bone density screening and preventive treatment, potentially catching bone loss before serious fractures occur.
What should psoriasis patients do to protect their bones?
Maintain adequate vitamin D levels (supplement if deficient), ensure sufficient calcium intake, do weight-bearing exercise regularly, and discuss steroid medication doses with your doctor. If identified as high-risk using the new prediction tool, ask your doctor about bone density screening and preventive treatments.
How accurate is this new bone loss prediction tool?
The tool demonstrated 82.4% accuracy in the training group and 77.1% accuracy when tested on new patients, indicating good reliability. However, it needs broader testing across different populations before widespread clinical adoption.
Want to Apply This Research?
- Track your vitamin D levels monthly and bone-healthy behaviors weekly (calcium intake, weight-bearing exercise minutes, steroid medication doses). Log any joint pain or psoriasis flare-ups, as these correlate with bone loss risk.
- Set reminders to take vitamin D supplements daily, aim for 30 minutes of weight-bearing exercise (walking, dancing, strength training) most days, and ensure adequate calcium intake through food or supplements. If taking steroids, discuss with your doctor about using the lowest effective dose.
- Schedule DXA screening based on your risk score. If high-risk, get baseline screening now and repeat every 1-2 years. Track vitamin D blood levels annually. Monitor for new joint symptoms or increased psoriasis severity, as these may indicate changing bone loss risk.
This research describes a predictive tool for osteoporosis risk in psoriasis patients and should not replace professional medical advice. If you have psoriasis, consult your dermatologist or rheumatologist about your individual bone health risk and whether screening is appropriate. This tool has been validated in one healthcare system and requires broader testing before widespread clinical use. Do not start, stop, or change any medications based on this information without medical guidance. Bone density screening and treatment decisions should be made with your healthcare provider based on your complete medical history.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.